M&A Deal Summary

Antech Diagnostics Acquires Eurolyser

On May 9, 2022, Antech Diagnostics acquired test/measurement equipment company Eurolyser from ArchiMed

Acquisition Highlights
  • This is Antech Diagnostics’ 1st transaction in the Test/Measurement Equipment sector.
  • This is Antech Diagnostics’ 1st transaction in Austria.

M&A Deal Summary
Date 2022-05-09
Target Eurolyser
Sector Test/Measurement Equipment
Buyer(s) Antech Diagnostics
Sellers(s) ArchiMed
Deal Type Add-on Acquisition

Target

Eurolyser

Salzburg, Austria
website
Eurolyser designs and engineers patented point-of-care testing equipment and kits, diagnosing a wide range of conditions in animals and humans. Point-of-care testing is done at the time of consultation, leading to the immediate availability of results and more timely, informed decisions concerning treatment. Eurolyser was founded in 2005 and is headquartered in Salzburg, Austria.

Search 192,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Antech Diagnostics

Irvine, California, United States

website

Category Company
Founded 1994
Sector Healthcare Services
DESCRIPTION

Antech Diagnostics, Inc. is an provider of health care services for animals.

DEAL STATS #
Overall 3 of 3
Sector (Test/Measurement Equipment) 1 of 1
Type (Add-on Acquisition) 2 of 2
Country (Austria) 1 of 1
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-10-23 Biovet

Saint-Hyacinthe, Quebec, Canada

Biovet, Inc. is a biotechnology company providing unique expertise in the field of diagnostics for animal health and agro-industry specialists in Canada and internationally. Biovet is based in Saint-Hyacinthe, Quebec.

Buy -

Seller(S) 1

SELLER

ArchiMed

Investor Investor Investor Investor Investor

website

Category Private Equity Firm
Founded 2014
Size Middle-Market
Type Sector Focused
DESCRIPTION

ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €5 to €300 million per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.

DEAL STATS #
Overall 3 of 5
Sector (Test/Measurement Equipment) 1 of 1
Type (Add-on Acquisition) 2 of 4
Country (Austria) 1 of 1
Year (2022) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-02-02 Fytexia

Vendres, France

Fytexia engages in the development of innovative, ready-to-use solutions dedicated to the dietary nutrition industry and validated by extensive third-party scientific research and testing. It has developed a unique offering around a range of 5 proprietary ingredients with demonstrable efficacy supported by clinical studies which have subsequently been published as peer-reviewed articles in well-cited scientific journals. Fytexia was formed in 2003 and is based in Vendres, France.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-12 Title21

Pleasanton, California, United States

Title21 is a specialized provider of paperless electronic services to cell & gene therapy labs. Title21’s clients include globally preeminent hospital and research institutions, including the Mayo Clinic, Memorial Sloan Kettering Cancer Center, Stanford University, Kaiser Permanente, and the University of Pennsylvania Health System. The fast-growing cell & gene therapy industry is transforming the treatment of life-threatening conditions including genetic disorders like spinal muscular atrophy, and diseases caused by vital infection, including COVID-19. Title21 was formed in 2001 and is based in Pleasanton, California.

Buy -
Mergr

Product

Company

Legal